Comparative Effectiveness and Safety of Efgartigimod in Generalized Myasthenia Gravis

Author(s)

ABSTRACT WITHDRAWN

OBJECTIVES: Myasthenia gravis (MG) is a rare autoimmune neuromuscular disease. Standard therapy usually includes corticosteroids and acetylcholinesterase inhibition. Other non-steroidal immunosuppressive or immunomodulatory therapies are often utilized including azathioprine (AZA), cyclophosphamide (CTX), methotrexate (MTX), mycophenolate mofetil (MMF); tacrolimus (TAC), intravenous immunoglobulin (IVIg), plasma exchange (PLEX); or monoclonal antibody therapies such as rituximab (RTX) or eculizumab (ECU). Efgartigimod (EFG) is a first-in-class antibody fragment which has shown favorable efficacy versus placebo in a Phase III trial in generalized MG [gMG]. However, no comparative effectiveness data are available. The aim of this study was to evaluate the comparative effectiveness and safety of EFG in gMG.

METHODS: A comprehensive systematic literature review was conducted using biomedical databases (Embase, Medline) and other sources (conferences, Cochrane Database) to identify randomized controlled trials of the above therapies in gMG. Clinical data across studies was extracted. A network meta‐analysis was performed on efficacy and safety endpoints for studies that met pre-specified inclusion criteria.

RESULTS: 15 Studies met the inclusion criteria. Among patients with gMG, 8 weeks of EFG was associated with a similar reduction from baseline QMG relative to placebo (mean difference: -2.46, 95% Credible Interval [CrI]: -5.85 to 0.6) compared to ECU (mean difference: -3.46, 95% CrI: -7.04 to -0.52), and superior to that of all other treatments (all mean differences vs. placebo -1.09 or greater). Among all treatments, patients receiving EFG had the lowest odds of experiencing a treatment-emergent adverse event relative to placebo (odds ratio [OR]: 0.66, 95% CrI: 0.27-1.58) or serious adverse event (OR: 0.46, 95% CrI: 0.14-1.54) of all treatments analyzed.

CONCLUSIONS: Efgartigimod has a favorable comparative effectiveness and safety profile versus currently available gMG treatments. Limitations of this study include heterogeneity of study populations, differences in treatment administration, and small sample sizes across trials.

Conference/Value in Health Info

2021-05, ISPOR 2021, Montreal, Canada

Value in Health, Volume 24, Issue 5, S1 (May 2021)

Code

PRO7

Topic

Clinical Outcomes

Topic Subcategory

Comparative Effectiveness or Efficacy

Disease

Neurological Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×